Replies to post #27986 on BioCurex, Inc.(fka BOCX)

[i_invest_utrade]

"If, during that period of time, the FDA determines that the “new” product is substantially similar to one that is already on the market, it will be approved without having to go through the normally required clinical trials"

I wonder if they are going to argue that the RECAF test is substantially similar to others already on the market just based on the fact that it's a cancer marker.

I think it's also positive that they are going to have their work peer reviewed. Essentially like a Proof of Concept.

Some would call any news fluff.

I also think we're dead in the water, but I am hoping the company proves me wrong.